carbamates and Depressive Disorder, Major

carbamates has been researched along with Depressive Disorder, Major in 4 studies

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)

A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity (NCT03043560)
Timeframe: baseline and 5 weeks

Change in Snaith-Hamilton Pleasure Scale (SHAPS)

"The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with strongly agree are coded as 1, while a strongly disagree response was assigned a score of 4. Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia." (NCT03043560)
Timeframe: baseline and 5 weeks

Change in Ventral Striatum (VS) Activation

"change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive.~Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate." (NCT03043560)
Timeframe: baseline and 5 weeks

Clinical Global Impression - Improvement (CGI-I)

A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT03043560)
Timeframe: baseline and 5 weeks

Clinical Global Impression - Severity (CGI-S)

Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT03043560)
Timeframe: baseline and 5 weeks

Montgomery-Asberg Depression Rating Scale (MADRS)

A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). (NCT03043560)
Timeframe: baseline and 5 weeks

Specific Loss of Interest and Pleasure Scale (SLIPS)

The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes. (NCT03043560)
Timeframe: baseline 5 weeks

Temporal Experience of Pleasure Scale (TEPS)

The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia. (NCT03043560)
Timeframe: baseline and 5 weeks

World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability. (NCT03043560)
Timeframe: baseline and 5 weeks

Trials

2 trials available for carbamates and Depressive Disorder, Major

Other Studies

2 other studies available for carbamates and Depressive Disorder, Major